Clinical Trial Detail

NCT ID NCT04068896
Title Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors NGM Biopharmaceuticals, Inc
Indications

stomach cancer

melanoma

colorectal cancer

pancreatic cancer

esophageal cancer

lung non-small cell carcinoma

urinary bladder cancer

head and neck squamous cell carcinoma

ovarian cancer

pancreatic adenocarcinoma

prostate cancer

Therapies

NGM120

Age Groups: adult senior

No variant requirements are available.